Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia : Results of a 24 week, double-blind, randomized Phase 3 trial

Show full item record



Permalink

http://hdl.handle.net/10138/224234

Citation

Roth , E M , Taskinen , M-R , Ginsberg , H N , Kastelein , J J P , Colhoun , H M , Robinson , J G , Merlet , L , Pordy , R & Baccara-Dinet , M T 2014 , ' Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia : Results of a 24 week, double-blind, randomized Phase 3 trial ' , International Journal of Cardiology , vol. 176 , no. 1 , pp. 55-61 . https://doi.org/10.1016/j.ijcard.2014.06.049

Title: Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia : Results of a 24 week, double-blind, randomized Phase 3 trial
Author: Roth, Eli M.; Taskinen, Marja-Riitta; Ginsberg, Henry N.; Kastelein, John J. P.; Colhoun, Helen M.; Robinson, Jennifer G.; Merlet, Laurence; Pordy, Robert; Baccara-Dinet, Marie T.
Other contributor: University of Helsinki, Research Programs Unit



Date: 2014-09
Language: eng
Number of pages: 7
Belongs to series: International Journal of Cardiology
ISSN: 0167-5273
DOI: https://doi.org/10.1016/j.ijcard.2014.06.049
URI: http://hdl.handle.net/10138/224234
Subject: PCSK9
Monoclonal antibodies
Cholesterol-lowering drugs
Hypercholesterolemia
LDL-C
Alirocumab
DENSITY-LIPOPROTEIN CHOLESTEROL
SUBTILISIN/KEXIN TYPE 9
MONOCLONAL-ANTIBODY
HEART-DISEASE
ATORVASTATIN
EFFICACY
SAFETY
LDL
METAANALYSIS
EVOLOCUMAB
3121 Internal medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0167527314011164_main.pdf 586.0Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record